Appearances are often deceptive

• References

• 1 Ayati N, Lee ST, Zakavi R. et al. Long-Acting Somatostatin Analog Therapy Differentially Alters (68)Ga-DOTATATE Uptake in Normal Tissues Compared with Primary Tumors and Metastatic Lesions. J Nucl Med 2018; 59: 223-227.
• 2 Boy C, Poeppel T, Kotzerke J. et al. [Somatostatin receptor PET/CT (SSTR-PET/CT)]. Nuklearmedizin 2018; 57: 4-17.
• 3 Caplin ME, Pavel M, Ruszniewski P. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014; 371: 1556-1557.
• 4 Froidevaux S, Hintermann E, Torok M, Macke HR, Beglinger C, Eberle AN. Differential regulation of somatostatin receptor type 2 (sst 2) expression in AR4–2J tumor cells implanted into mice during octreotide treatment. Cancer Res 1999; 59: 3652-3657.
• 5 Haug AR, Rominger A, Mustafa M. et al. Treatment with octreotide does not reduce tumor uptake of (68)Ga-DOTATATE as measured by PET/CT in patients with neuroendocrine tumors. J Nucl Med 2011; 52: 1679-1683.
• 6 Rinke A, Muller HH, Schade-Brittinger C. et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27: 4656-4663.
• 7 Taelman VF, Radojewski P, Marincek N. et al. Upregulation of Key Molecules for Targeted Imaging and Therapy. J Nucl Med 2016; 57: 1805-1810.
• 8 Waser B, Tamma ML, Cescato R, Maecke HR, Reubi JC. Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues. J Nucl Med 2009; 50: 936-941.